Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.

Ong DM, Ashby M, Grigg A, Gard G, Ng ZY, Huang HE, Chong YS, Cheah CY, Devitt B, Chong G, Loh Z, Mo A, Hawkes EA.

Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16049. [Epub ahead of print]

PMID:
31206608
2.

Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.

van Zelm MC, Pumar M, Shuttleworth P, Aui PM, Smart JM, Grigg A, Bosco JJ.

Front Immunol. 2019 Apr 26;10:895. doi: 10.3389/fimmu.2019.00895. eCollection 2019.

3.

Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.

Hamadi A, Grigg AP, Dobie G, Burbury KL, Schwarer AP, Kwa FA, Jackson DE.

Thromb Haemost. 2019 May 12. doi: 10.1055/s-0039-1688787. [Epub ahead of print]

PMID:
31079415
4.

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.

Minson AG, Cummins K, Fox L, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A.

Blood Adv. 2019 Apr 9;3(7):1084-1091. doi: 10.1182/bloodadvances.2018028035.

5.

Is there a role for proton pump inhibitor prophylaxis in haematology patients?

Leitinger E, Hui L, Grigg A.

Intern Med J. 2019 Jun;49(6):694-701. doi: 10.1111/imj.14241. Review.

PMID:
30719802
6.

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.

Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A.

Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1551533. [Epub ahead of print]

PMID:
30632843
7.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

8.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

9.

Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.

Forsyth CJ, Chan WH, Grigg AP, Cook NC, Lane SW, Burbury KL, Perkins AC, Ross DM.

Intern Med J. 2018 Nov 8. doi: 10.1111/imj.14154. [Epub ahead of print] Review.

PMID:
30411442
10.

Cerebral toxoplasmosis in a patient with prolonged CD4 lymphopenia post autologous hemopoietic stem cell transplant.

van Mourik A, Grigg A.

Leuk Lymphoma. 2019 Feb;60(2):544-546. doi: 10.1080/10428194.2018.1485906. Epub 2018 Nov 8. No abstract available.

PMID:
30407076
11.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

PMID:
30315232
12.

Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients.

Grigg SE, Date P, Loh Z, Estacio O, Johnson DF, Hawkes EA, Grigg A.

Support Care Cancer. 2019 Apr;27(4):1223-1227. doi: 10.1007/s00520-018-4476-7. Epub 2018 Sep 27.

PMID:
30259115
13.

The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.

Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A.

Ann Hematol. 2018 Dec;97(12):2509-2518. doi: 10.1007/s00277-018-3447-x. Epub 2018 Jul 26.

PMID:
30051172
14.

Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission.

Hawkes EA, Loh Z, Estacio O, Chong G, Ha FJ, Gilbertson M, Grigg A.

Br J Cancer. 2018 Aug;119(5):546-550. doi: 10.1038/s41416-018-0183-x. Epub 2018 Jul 23.

PMID:
30033446
15.

Mercury isotope signatures of digests and sequential extracts from industrially contaminated soils and sediments.

Grigg ARC, Kretzschmar R, Gilli RS, Wiederhold JG.

Sci Total Environ. 2018 Sep 15;636:1344-1354. doi: 10.1016/j.scitotenv.2018.04.261. Epub 2018 May 5.

PMID:
29913595
16.

Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.

Wong E, Davis JE, Grigg A, Szer J, Ritchie D.

Bone Marrow Transplant. 2019 Feb;54(2):175-189. doi: 10.1038/s41409-018-0244-z. Epub 2018 Jun 14.

PMID:
29904127
17.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF.

J Clin Oncol. 2018 Sep 1;36(25):2657-2658. doi: 10.1200/JCO.2018.78.6137. Epub 2018 May 31. No abstract available.

PMID:
29851544
18.

Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine.

Prabahran A, Tacey M, Fleming S, Wei A, Tate C, Marlton P, Wight J, Grigg A, Tuckfield A, Szer J, Ritchie D, Chee L.

Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13089. [Epub ahead of print]

PMID:
29719925
19.

Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.

Wight JC, Chong G, Grigg AP, Hawkes EA.

Blood Rev. 2018 Sep;32(5):400-415. doi: 10.1016/j.blre.2018.03.005. Epub 2018 Mar 26. Review.

PMID:
29605154
20.

Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing.

Lopez JA, Noori T, Minson A, Li Jovanoska L, Thia K, Hildebrand MS, Akhlaghi H, Darcy PK, Kershaw MH, Brown NJ, Grigg A, Trapani JA, Voskoboinik I.

Front Immunol. 2018 Mar 15;9:529. doi: 10.3389/fimmu.2018.00529. eCollection 2018.

21.

An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.

Wight JC, Hawkes EA, Berlangieri SU, Khor R, Grigg AP.

Leuk Lymphoma. 2018 Nov;59(11):2749-2751. doi: 10.1080/10428194.2018.1452217. Epub 2018 Mar 23. No abstract available.

PMID:
29569979
22.

Echocardiography has low utility in cancer patients with Staphylococcus aureus bacteraemia: findings from a retrospective study.

Loh Z, Estacio O, Grigg A, Holmes NE, Chong G, Hawkes EA.

Support Care Cancer. 2018 Sep;26(9):3083-3089. doi: 10.1007/s00520-018-4162-9. Epub 2018 Mar 21.

PMID:
29564624
23.

Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.

Minson A, Douglas G, Bilmon I, Grigg A.

Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13. No abstract available.

PMID:
29532918
24.

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, Dickinson M, Campbell P, Hempton J, King H, Dowsing C, Bergin K, Muir S, Gibbs S, Grigg A.

Bone Marrow Transplant. 2018 Sep;53(9):1116-1123. doi: 10.1038/s41409-018-0152-2. Epub 2018 Mar 9.

PMID:
29523889
25.

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A.

Blood Adv. 2017 May 15;1(13):802-811. doi: 10.1182/bloodadvances.2016003889. eCollection 2017 May 23.

26.

Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy.

Estacio O, Loh Z, Baker A, Chong G, Grigg A, Churilov L, Hawkes EA.

Intern Med J. 2018 May;48(5):556-560. doi: 10.1111/imj.13712.

PMID:
29227565
27.

Allogeneic stem cell transplantation as a risk factor for recurrent melanoma.

Stevens H, Raj K, Ashby M, Grigg A.

Leuk Lymphoma. 2018 Jul;59(7):1750-1752. doi: 10.1080/10428194.2017.1393670. Epub 2017 Oct 31. No abstract available.

PMID:
29087220
28.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382. No abstract available.

PMID:
29029280
29.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3501.

PMID:
28961714
30.

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome.

Mo A, Testro A, French J, Robertson M, Angus P, Grigg A.

Intern Med J. 2017 Dec;47(12):1361-1367. doi: 10.1111/imj.13544.

PMID:
28675622
31.

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.

Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E.

Bone Marrow Transplant. 2017 Sep;52(9):1288-1293. doi: 10.1038/bmt.2017.108. Epub 2017 Jun 19.

PMID:
28628088
32.

Assessment of Behavioral Disruption in Rats with Abdominal Inflammation Using Visual Cue Titration and the Five-choice Serial-reaction Time Task.

Martin TJ, Strassburg TJ, Grigg AL, Kim SA, Ririe DG, Eisenach JC.

Anesthesiology. 2017 Aug;127(2):372-381. doi: 10.1097/ALN.0000000000001702.

33.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
34.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG).

Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10.

35.

Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?

Hawkes EA, Chong G, Grigg A.

J Clin Oncol. 2017 Jan 20;35(3):371-372. doi: 10.1200/JCO.2016.68.2047. Epub 2016 Oct 28. No abstract available.

PMID:
28095269
36.

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, Grigg A.

Ann Oncol. 2017 Apr 1;28(4):836-842. doi: 10.1093/annonc/mdw685.

PMID:
28031173
37.

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Grigg A, Dyer MJ, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E, Marlton P.

Haematologica. 2017 Apr;102(4):765-772. doi: 10.3324/haematol.2016.152272. Epub 2016 Dec 23.

38.

Use of computed tomography abdomen and pelvis for investigation of febrile neutropenia in adult haematology patients.

Lim HY, Ashby M, Williams B, Grigg A.

Intern Med J. 2016 Nov;46(11):1332-1336. doi: 10.1111/imj.13235.

PMID:
27813352
39.

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.

Eur J Haematol. 2017 Feb;98(2):97-105. doi: 10.1111/ejh.12793. Epub 2016 Sep 20.

PMID:
27537786
40.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

Jeong W, Haywood P, Shanmuganathan N, Lindsay J, Urbancic K, Ananda-Rajah MR, Chen SC, Bajel A, Ritchie D, Grigg A, Seymour JF, Peleg AY, Kong DC, Slavin MA.

J Antimicrob Chemother. 2016 Dec;71(12):3540-3547. Epub 2016 Aug 11.

PMID:
27521358
41.

The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.

Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M, Hamadi A, Grigg AP, Jackson DE.

Thromb Res. 2016 Sep;145:54-64. doi: 10.1016/j.thromres.2016.07.019. Epub 2016 Jul 30.

PMID:
27494773
42.

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.

Douglas G, Harrison C, Forsyth C, Bennett M, Stevenson W, Hounsell J, Ratnasingam S, Ritchie D, Ross DM, Grigg A.

Leuk Lymphoma. 2017 Jan;58(1):89-95. Epub 2016 Jul 25.

PMID:
27454522
43.

Fanconi anemia in 55-year-old identical twins first presenting as fatal post-chemotherapy pancytopenia.

Stevens H, Chyn Chua C, Wallis M, Hew S, Grigg A.

Am J Hematol. 2016 Dec;91(12):1273-1276. doi: 10.1002/ajh.24488. Epub 2016 Aug 8. No abstract available.

44.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL.

Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.

PMID:
27416909
45.
46.

Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.

Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.

Ann Hematol. 2016 Apr;95(5):809-16. doi: 10.1007/s00277-016-2611-4. Epub 2016 Feb 15.

PMID:
26878861
47.

Characterizing Key Components of a Medical Home Among Rural Adolescents.

Dixon SK, Hoopes AJ, Benkeser D, Grigg A, Grow HM.

J Adolesc Health. 2016 Feb;58(2):141-7. doi: 10.1016/j.jadohealth.2015.10.249.

PMID:
26802989
48.

Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.

Lasica M, Taylor E, Bhattacharyya P, Bennett A, Cooke RE, Stern C, Agresta F, Ayton R, Grigg A.

Eur J Haematol. 2016 Oct;97(4):348-52. doi: 10.1111/ejh.12737. Epub 2016 Feb 23.

PMID:
26773518
49.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.

PMID:
26685769
50.

Do state-and-transition models derived from vegetation succession also represent avian succession in restored mine pits?

Craig MD, Stokes VL, Fontaine JB, Hardy GE, Grigg AH, Hobbs RJ.

Ecol Appl. 2015 Oct;25(7):1790-806.

PMID:
26591446

Supplemental Content

Support Center